Ignite Creation Date:
2024-05-05 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479648
Status:
COMPLETED
Last Update Posted:
2016-07-19
First Post:
2007-05-25
Brief Title:
A Phase 2 Study of Immunogenicity Safety and Tolerability of CSL412 in Elderly Participants
Sponsor:
Seqirus
Organization:
Seqirus
Study Overview
Official Title:
A Phase II Double-Blind Randomised Controlled Multi-Centre Study to Evaluate the Immunogenicity Safety and Tolerability of Three Formulations of CSL412 in Adults 18 to 45 Years and Older Adults 60 Years
Status:
COMPLETED
Status Verified Date:
2008-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Current influenza vaccines have a reduced efficacy in the elderly This study will investigate the immunogenicity safety and tolerability of an adjuvanted influenza vaccine in elderly participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None